

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中國管業集團有限公司
CHINA PIPE GROUP LIMITED

(incorporated in Bermuda with limited liability)
(Stock Code: 380)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Dr. ZIA, Samuel will be appointed as a non-executive director of the Company with effect from 21 July 2010.

The board of directors (the “Board”) of China Pipe Group Limited (the “Company”) is pleased to announce that Dr. ZIA, Samuel (“Dr. Zia”) will be appointed as a non-executive director of the Company with effect from 21 July 2010.

Dr. Zia, aged 56, he holds a Bachelor of Science in Biochemistry from University of California at Los Angeles (UCLA), U.S.A. and a Doctorate in Medicine University of Southern California at Los Angeles, California (USC), U.S.A. Since October 2009, he was appointed as managing director in Citfair Limited. Prior to that, he was appointed as Chief Executive Officer in Uni-Bio Science Group Limited which was listed on the Main Board of The Stock Exchange of Hong Kong Limited (“Hong Kong Stock Exchange”) from January 2007 to October 2009. Recently, he was appointed as associate director in DJ Capital Limited since March 2010. He has solid experience at management level for over 20 years.

Save as disclosed above, Dr. Zia did not hold any directorships in other listed public companies in the last three years and he has no other major appointments and professional qualifications.

An appointment letter will be signed by Dr. Zia and the Company. Dr. Zia will be entitled to a director fee of HK\$150,000 per annum, which was determined with reference to his duties and responsibilities, qualification and experience and the prevailing market conditions. Dr. Zia will be appointed for a term from 21 July 2010 to 31 December 2011 and will be subject to retirement by rotation and re-election in

general meeting in accordance with the bye-laws of the Company.

Dr. Zia does not hold any other position in the Company or any subsidiaries of the Company.

Dr. Zia does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company (as respectively defined in The Rules Governing the Listing of Securities on Hong Kong Stock Exchange (the “Listing Rules”). As at the date of this announcement, Dr. Zia does not have any interest in shares of the Company and its associated companies within the meaning of Part XV of the Securities and Futures Ordinance.

As at the date of this announcement, to the best of the knowledge, information and belief of the directors of the Company having made reasonable enquiry, save as disclosed herein, there is no information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules in relation to the appointment of Dr. Zia as a non-executive director of the Company and there are no other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warmest welcome to Dr. Zia for joining the Board of the Company.

By Order of the Board

Lai Guanglin

Chairman

Hong Kong, 21 July 2010

As at the date of this announcement, the Board consists of Mr. Yu Ben Ansheng, Mr. Sam Ming Choy, Mr. Lai Fulin as executive directors, Mr. Lai Guanglin, Mr. U Kean Seng and Mr. Zhao Yue as non-executive directors; and Mr. Wong Yee Shuen, Wilson, Mr. Chen Wei Wen and Ms. Wu Xiuru as independent non-executive directors.